BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, Ellis LM. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg. 1997;132:541-546. [PMID: 9161399 DOI: 10.1001/archsurg.1997.01430290087018] [Cited by in Crossref: 226] [Cited by in F6Publishing: 212] [Article Influence: 9.4] [Reference Citation Analysis]
Number Citing Articles
1 Barthomeuf C, Lamy S, Blanchette M, Boivin D, Gingras D, Béliveau R. Inhibition of sphingosine-1-phosphate- and vascular endothelial growth factor-induced endothelial cell chemotaxis by red grape skin polyphenols correlates with a decrease in early platelet-activating factor synthesis. Free Radical Biology and Medicine 2006;40:581-90. [DOI: 10.1016/j.freeradbiomed.2005.09.015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
2 Zafirellis K, Agrogiannis G, Zachaki A, Gravani K, Karameris A, Kombouras C. Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J Surg Res. 2008;147:99-107. [PMID: 17655863 DOI: 10.1016/j.jss.2007.05.041] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
3 Giatromanolaki A, Sivridis E, Koukourakis MI. Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol. 2006;29:408-417. [PMID: 16891872 DOI: 10.1097/01.coc.0000221317.56731.4e] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 3.7] [Reference Citation Analysis]
4 Milburn Jessup J. Tumor markers – prognostic and therapeutic implications for colorectal carcinoma. Surgical Oncology 1998;7:139-51. [DOI: 10.1016/s0960-7404(99)00028-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
5 Compton CC. Pathologic Staging of Colorectal Cancer: An Advanced Users??? Guide. Pathology Case Reviews 2004;9:150-62. [DOI: 10.1097/01.pcr.0000132990.56528.50] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
6 Compton CC. Pathologic Prognostic Factors in the Recurrence of Rectal Cancer. Clinical Colorectal Cancer 2002;2:149-60. [DOI: 10.3816/ccc.2002.n.020] [Cited by in Crossref: 47] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
7 Matsuda Y, Hagio M, Ishiwata T. Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis. World J Gastroenterol. 2013;19:42-48. [PMID: 23326161 DOI: 10.3748/wjg.v19.i1.42] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 64] [Article Influence: 9.1] [Reference Citation Analysis]
8 Potti A, Moazzam N, Langness E, Sholes K, Tendulkar K, Koch M, Kargas S. Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. J Cancer Res Clin Oncol 2004;130:80-6. [PMID: 14634801 DOI: 10.1007/s00432-003-0509-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
9 Koukourakis MI, Mavanis I, Kouklakis G, Pitiakoudis M, Minopoulos G, Manolas C, Simopoulos C. Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging. Am J Clin Oncol. 2007;30:315-318. [PMID: 17551312 DOI: 10.1097/01.coc.0000258119.90805.ca] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
10 Zhang L, Lin X, Wang W, Zhuang X, Dong J, Qi Z, Hu Q. Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. Plast Reconstr Surg 2005;116:200-4. [PMID: 15988268 DOI: 10.1097/01.prs.0000170804.80834.5f] [Cited by in Crossref: 65] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
11 Calvo HJ, Ortega GD, Pardo RJM, López , MAJ , Cubo T. Biologia molecular del processo metastásico del cancer colorectal. Cirugia Española. 2000;68:577-587. [PMID: 12810454 DOI: 10.1093/annonc/mdg725] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
12 Chen CH, Hsieh MC, Hsiao PK, Lin EK, Lu YJ, Wu SY. A critical reappraisal for the value of tumor size as a prognostic variable in rectal adenocarcinoma. J Cancer 2017;8:1927-34. [PMID: 28819391 DOI: 10.7150/jca.17930] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
13 Bruns CJ, Liu W, Davis DW, Shaheen RM, Mcconkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000;89:488-99. [DOI: 10.1002/1097-0142(20000801)89:3<488::aid-cncr3>3.0.co;2-x] [Cited by in Crossref: 123] [Article Influence: 5.9] [Reference Citation Analysis]
14 Mineta H, Miura K, Ogino T, Takebayashi S, Misawa K, Ueda Y, Suzuki I, Dictor M, Borg A, Wennerberg J. Prognostic value of Vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br J Cancer. 2000;83:775-781. [PMID: 10952783 DOI: 10.1054/bjoc.2000.1357] [Cited by in Crossref: 88] [Cited by in F6Publishing: 69] [Article Influence: 4.2] [Reference Citation Analysis]
15 Kimura Y, Morohashi S, Yoshizawa T, Suzuki T, Morohashi H, Sakamoto Y, Koyama M, Murata A, Kijima H, Hakamada K. Clinicopathological significance of vascular endothelial growth factor, thymidine phosphorylase and microvessel density in colorectal cancer. Mol Med Rep 2016;13:1551-7. [PMID: 26676225 DOI: 10.3892/mmr.2015.4687] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
16 Duff SE, Jeziorska M, Kumar S, Haboubi N, Sherlock D, O'Dwyer ST, Jayson GC. Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer. Colorectal Dis. 2007;9:793-800. [PMID: 17931169 DOI: 10.1111/j.1463-1318.2006.01199.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
17 Wei J, Yan W, Li X, Ding Y, Tai H. Thromboxane receptor α mediates tumor growth and angiogenesis via induction of vascular endothelial growth factor expression in human lung cancer cells. Lung Cancer 2010;69:26-32. [DOI: 10.1016/j.lungcan.2009.09.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
18 Sakamoto T, Saito H, Tatebe S, Tsujitani S, Ozaki M, Ito H, Ikeguchi M. Interleukin-10 expression significantly correlates with minor CD8 + T-cell infiltration and high microvessel density in patients with gastric cancer: IL-10 Expression in Gastric Cancer. Int J Cancer 2006;118:1909-14. [DOI: 10.1002/ijc.21598] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
19 Citak EC, Oguz A, Karadeniz C, Akyurek N. Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma. Pathology - Research and Practice 2008;204:89-96. [DOI: 10.1016/j.prp.2007.11.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
20 Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL, Perret GY. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006;94:1823-32. [PMID: 16773076 DOI: 10.1038/sj.bjc.6603176] [Cited by in Crossref: 238] [Cited by in F6Publishing: 214] [Article Influence: 15.9] [Reference Citation Analysis]
21 Parikh AA, Fan F, Liu WB, Ahmad SA, Stoeltzing O, Reinmuth N, Bielenberg D, Bucana CD, Klagsbrun M, Ellis LM. Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol 2004;164:2139-51. [PMID: 15161648 DOI: 10.1016/S0002-9440(10)63772-8] [Cited by in Crossref: 117] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
22 Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist. 2000;5 Suppl 1:11-15. [PMID: 10804085 DOI: 10.1634/theoncologist.5-suppl_1-11] [Cited by in Crossref: 134] [Cited by in F6Publishing: 123] [Article Influence: 6.4] [Reference Citation Analysis]
23 Lim C, Cauchy F, Azoulay D, Farges O, Ronot M, Pocard M. Tumour progression and liver regeneration--insights from animal models. Nat Rev Gastroenterol Hepatol. 2013;10:452-462. [PMID: 23567217 DOI: 10.1038/nrgastro.2013.55] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
24 Ikubo A, Aoki Y, Nagai E, Suzuki T. Highly metastatic variant of a mouse colon carcinoma cell line, LM17 and its response to GM-CSF gene therapy. Clin Exp Metastasis 1999;17:849-55. [PMID: 11089883 DOI: 10.1023/a:1006730320248] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
25 Saad RS, Kordunsky L, Liu YL, Denning KL, Kandil HA, Silverman JF. Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod Pathol. 2006;19:1317-1323. [PMID: 16799477 DOI: 10.1038/modpathol.3800651] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 5.1] [Reference Citation Analysis]
26 Lee SH, Jeung IC, Park TW, Lee K, Lee DG, Cho YL, Lee TS, Na HJ, Park YJ, Lee HG, Jeong MS, Bae KH, Lee SC, Lee HJ, Kwon YG, Hong HJ, Kim JS, Min JK. Extension of the in vivo half-life of endostatin and its improved anti-tumor activities upon fusion to a humanized antibody against tumor-associated glycoprotein 72 in a mouse model of human colorectal carcinoma. Oncotarget 2015;6:7182-94. [PMID: 25762629 DOI: 10.18632/oncotarget.3121] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
27 Kim HS, Kang HS, Messam CA, Min KW, Park CS. Comparative evaluation of angiogenesis in gastric adenocarcinoma by nestin and CD34. Appl Immunohistochem Mol Morphol 2002;10:121-7. [PMID: 12051629 DOI: 10.1097/00129039-200206000-00005] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
28 Kawczyk-krupka A, Sieroń-stołtny K, Latos W, Czuba Z, Kwiatek B, Potempa M, Wasilewska K, Król W, Stanek A. ALA-induced photodynamic effect on vitality, apoptosis, and secretion of vascular endothelial growth factor (VEGF) by colon cancer cells in normoxic environment in vitro. Photodiagnosis and Photodynamic Therapy 2016;13:308-15. [DOI: 10.1016/j.pdpdt.2015.09.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
29 Okugawa Y, Miki C, Toiyama Y, Koike Y, Inoue Y, Kusunoki M. Serum level of soluble vascular cell adhesion molecule 1 is a valuable prognostic marker in colorectal carcinoma. Dis Colon Rectum. 2009;52:1330-1336. [PMID: 19571712 DOI: 10.1007/dcr.0b013e3181a0d144] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
30 Ellis LM. Antiangiogenic therapy: more promise and, yet again, more questions. J Clin Oncol 2003;21:3897-9. [PMID: 14517185 DOI: 10.1200/JCO.2003.07.977] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
31 Dassoulas K, Gazouli M, Theodoropoulos G, Christoni Z, Rizos S, Zisi-Serbetzoglou A, Glava C, Karantanos T, Klonaris C, Karakitsos P. Vascular endothelial growth factor and endoglin expression in colorectal cancer. J Cancer Res Clin Oncol 2010;136:703-8. [PMID: 19890661 DOI: 10.1007/s00432-009-0709-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
32 Landriscina M, Cassano A, Ratto C, Longo R, Ippoliti M, Palazzotti B, Crucitti F, Barone C. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer. 1998;78:765-770. [PMID: 9743297 DOI: 10.1038/bjc.1998.575] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 2.6] [Reference Citation Analysis]
33 Yeo DM, Oh SN, Jung CK, Lee MA, Oh ST, Rha SE, Jung SE, Byun JY, Gall P, Son Y. Correlation of dynamic contrast-enhanced MRI perfusion parameters with angiogenesis and biologic aggressiveness of rectal cancer: Preliminary results. J Magn Reson Imaging. 2015;41:474-480. [PMID: 24375840 DOI: 10.1002/jmri.24541] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
34 Cascinu S, Graziano F, Valentini M, Catalano V, Giordani P, Staccioli M, Rossi C, Baldelli A, Grianti C, Muretto P, Catalano G. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: Relationships with tumor recurrence and resistance to adjuvant chemotherapy. Annals of Oncology 2001;12:239-44. [DOI: 10.1023/a:1008339408300] [Cited by in Crossref: 37] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
35 Pei X, Liu Y, Sun L, Zhang J, Fang Y, Liao X, Liu J, Zhang C, Yin T. Outcome of Molecular Targeted Agents Plus Chemotherapy for Second-Line Therapy of Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Trials. Clinical Colorectal Cancer 2016;15:e149-56. [DOI: 10.1016/j.clcc.2016.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697-3705. [PMID: 15738537 DOI: 10.1200/jco.2005.05.112] [Cited by in Crossref: 652] [Cited by in F6Publishing: 201] [Article Influence: 40.8] [Reference Citation Analysis]
37 Rothenberg ML. Current Approaches to First-Line Treatment of Advanced Colorectal Cancer. Clinical Colorectal Cancer 2004;4:S16-21. [DOI: 10.3816/ccc.2004.s.003] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
38 Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol. 2004;17:197-203. [PMID: 14657950 DOI: 10.1038/modpathol.3800034] [Cited by in Crossref: 121] [Cited by in F6Publishing: 105] [Article Influence: 7.1] [Reference Citation Analysis]
39 Ochs AM, Wong L, Kakani V, Neerukonda S, Gorske J, Rao A, Riggs M, Ward H, Keville L. Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer. 2004;4:262-267. [PMID: 15555209 DOI: 10.3816/ccc.2004.n.025] [Cited by in Crossref: 33] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
40 Paydas S, Zorludemir S, Baslamisli F, Tuncer I. Vascular Endothelial Growth Factor (VEGF) Expression in Plasmacytoma. Leukemia & Lymphoma 2009;43:139-43. [DOI: 10.1080/10428190210203] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
41 Rajaganeshan R, Prasad R, Guillou PJ, Chalmers CR, Scott N, Sarkar R, Poston G, Jayne DG. The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. Br J Cancer. 2007;96:1112-1117. [PMID: 17353920 DOI: 10.1038/sj.bjc.6603677] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 4.0] [Reference Citation Analysis]
42 Wang TF, Lockhart AC. Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol 2012;6:19-30. [PMID: 22253552 DOI: 10.4137/CMO.S7432] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
43 Graziano F, Catalano V, Baldelli AM, Cascinu S. Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy. Expert Rev Anticancer Ther. 2001;1:247-257. [PMID: 12113030 DOI: 10.1586/14737140.1.2.247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
44 Martinelli E, Troiani T, Morgillo F, Orditura M, De Vita F, Belli G, Ciardiello F. Emerging VEGF-receptor inhibitors for colorectal cancer. Expert Opin Emerg Drugs. 2013;18:25-37. [PMID: 23216053 DOI: 10.1517/14728214.2013.749856] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
45 Ishikawa H, Fujii H, Yamamoto K, Morita T, Hata M, Koyama F, Terauchi S, Sugimori S, Kobayashi T, Enomoto H, Yoshikawa S, Nishikawa T, Nakano H. Tumor angiogenesis predicts recurrence with normal serum carcinoembryonic antigen in advanced rectal carcinoma patients. Surg Today 1999;29:983-91. [PMID: 10554319 DOI: 10.1007/s005950050633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
46 Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol. 2003;14:1026-1038. [PMID: 12853343 DOI: 10.1093/annonc/mdg284] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 4.9] [Reference Citation Analysis]
47 Rougier P. Palliative and adjuvant chemotherapy in colorectal cancer. European Journal of Cancer 2001;37:189-202. [DOI: 10.1016/s0959-8049(01)80020-4] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
48 Matsuura T, Fukuda Y, Fujitaka T, Nishisaka T, Sakatani T, Ito H. Preoperative treatment with tegafur suppositories enhances apoptosis and reduces the intratumoral microvessel density of human colorectal carcinoma. Cancer 2000;88:1007-15. [PMID: 10699888 DOI: 10.1002/(sici)1097-0142(20000301)88:5<1007::aid-cncr9>3.0.co;2-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
49 García-Alfonso P, Ferrer A, Gil S, Dueñas R, Pérez MT, Molina R, Capdevila J, Safont MJ, Castañón C, Cano JM, Lara R. Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. Target Oncol 2015;10:453-65. [PMID: 25752908 DOI: 10.1007/s11523-015-0362-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
50 Yonenaga Y, Mori A, Onodera H, Yasuda S, Oe H, Fujimoto A, Tachibana T, Imamura M. Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology 2005;69:159-66. [PMID: 16127287 DOI: 10.1159/000087840] [Cited by in Crossref: 122] [Cited by in F6Publishing: 101] [Article Influence: 7.6] [Reference Citation Analysis]
51 Zhang X, Chen L. The recent progress of the mechanism and regulation of tumor necrosis in colorectal cancer. J Cancer Res Clin Oncol 2016;142:453-63. [PMID: 26094047 DOI: 10.1007/s00432-015-1997-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
52 De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer. 2004;100:270-278. [PMID: 14716760 DOI: 10.1002/cncr.11911] [Cited by in Crossref: 79] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]
53 Ramachandra S, D'souza SS, Gururaj AE, Shaila MS, Salimath BP. Paracrine action of sFLT-1 secreted by stably-transfected Ehrlich ascites tumor cells and therapy using sFLT-1 inhibits ascites tumor growth in vivo. J Gene Med 2009;11:422-34. [DOI: 10.1002/jgm.1309] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
54 Kline CL, El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) 2013;6:988-1038. [PMID: 24276379 DOI: 10.3390/ph6080988] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
55 Giatromanolaki A, Koukourakis MI, Sivridis E, Chlouverakis G, Vourvouhaki E, Turley H, Harris AL, Gatter KC. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest 2007;37:878-86. [PMID: 17883421 DOI: 10.1111/j.1365-2362.2007.01866.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
56 Bruns CJ, Ellis LM, Radinsky R. Antiangiogenic Strategies in Pancreatic Cancer. In: Evans DB, Pisters PWT, Abbruzzese JL, editors. Pancreatic Cancer. New York: Springer-Verlag; 2002. pp. 357-67. [DOI: 10.1007/0-387-21600-6_34] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
57 van der Jagt MF, Wobbes T, Strobbe LJ, Sweep FC, Span PN. Metalloproteinases and their regulators in colorectal cancer: MP Regulators in Colorectal Cancer. J Surg Oncol 2010;101:259-69. [DOI: 10.1002/jso.21462] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
58 Rhee J, Hoff PM. Angiogenesis inhibitors in the treatment of cancer. Expert Opinion on Pharmacotherapy 2005;6:1701-11. [DOI: 10.1517/14656566.6.10.1701] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
59 Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer. 2000;36:748-753. [PMID: 10762747 DOI: 10.1016/s0959-8049(00)00003-4] [Cited by in Crossref: 197] [Cited by in F6Publishing: 71] [Article Influence: 9.4] [Reference Citation Analysis]
60 Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecologic Oncology 2006;102:425-8. [DOI: 10.1016/j.ygyno.2006.05.018] [Cited by in Crossref: 95] [Cited by in F6Publishing: 70] [Article Influence: 6.3] [Reference Citation Analysis]
61 Fujita S, Nakanisi Y, Taniguchi H, Yamamoto S, Akasu T, Moriya Y, Shimoda T. Cancer Invasion to Auerbach's Plexus is an Important Prognostic Factor in Patients with pT3-pT4 Colorectal Cancer. Diseases of the Colon & Rectum 2007;50:1860-6. [DOI: 10.1007/s10350-007-9072-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
62 Kusumanto YH, Tio RA, Loef BG, Sluiter WJ, Mulder NH, Hospers GAP. Systemic VEGF levels after coronary artery bypass graft surgery reflects the extent of inflammatory response. Acute Cardiac Care 2009;8:41-5. [DOI: 10.1080/14628840500480449] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
63 Ono T, Miki C. Factors influencing tissue concentration of vascular endothelial growth factor in colorectal carcinoma. Am J Gastroenterology 2000;95:1062-7. [DOI: 10.1111/j.1572-0241.2000.01909.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
64 Razavi ZS, Asgarpour K, Mahjoubin-Tehran M, Rasouli S, Khan H, Shahrzad MK, Hamblin MR, Mirzaei H. Angiogenesis-related non-coding RNAs and gastrointestinal cancer. Mol Ther Oncolytics 2021;21:220-41. [PMID: 34095461 DOI: 10.1016/j.omto.2021.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
65 Carneiro CS, de Queiroz GF, Pinto AC, Dagli ML, Matera JM. Feline injection site sarcoma: immunohistochemical characteristics. Journal of Feline Medicine and Surgery 2019;21:314-21. [DOI: 10.1177/1098612x18774709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Yamaguchi K, Saito H, Oro S, Tatebe S, Ikeguchi M, Tsujitani S. Expression of inducible nitric oxide synthase is significantly correlated with expression of vascular endothelial growth factor and dendritic cell infiltration in patients with advanced gastric carcinoma. Oncology. 2005;68:471-478. [PMID: 16020977 DOI: 10.1159/000086990] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
67 Birkhahn M, Mitra AP, Williams AJ, Lam G, Ye W, Datar RH, Balic M, Groshen S, Steven KE, Cote RJ. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol 2010;57:12-20. [PMID: 19762144 DOI: 10.1016/j.eururo.2009.09.013] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
68 Compton CC. Surgical Pathology of Colorectal Cancer. In: Saltz LB, editor. Colorectal Cancer. Totowa: Humana Press; 2002. pp. 247-65. [DOI: 10.1007/978-1-59259-160-2_14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
69 Yokoyama Y, Sato S, Futagami M, Fukushi Y, Sakamoto T, Umemoto M, Saito Y. Prognostic Significance of Vascular Endothelial Growth Factor and Its Receptors in Endometrial Carcinoma. Gynecologic Oncology 2000;77:413-8. [DOI: 10.1006/gyno.2000.5802] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 2.1] [Reference Citation Analysis]
70 Staton CA, Koay I, Wu JM, Hoh L, Reed MWR, Brown NJ. Neuropilin-1 and neuropilin-2 expression in the adenoma-carcinoma sequence of colorectal cancer. Histopathology 2013;62:908-15. [DOI: 10.1111/his.12098] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
71 Lim C, Eveno C, Pocard M. [Microenvironment and colorectal liver metastases angiogenesis: surgical implications]. Bull Cancer. 2013;100:343-350. [PMID: 23532039 DOI: 10.1684/bdc.2013.1725] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
72 Boxer GM, Tsiompanou E, Levine T, Watson R, Begent RH. Immunohistochemical expression of vascular endothelial growth factor and microvessel counting as prognostic indicators in node-negative colorectal cancer. Tumour Biol. 2005;26:1-8. [PMID: 15741766 DOI: 10.1159/000084180] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
73 Nordman IC, Iyer S, Joshua AM, Clarke SJ. ADVANCES IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER. ANZ J Surg 2006;76:373-80. [DOI: 10.1111/j.1445-2197.2006.03726.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
74 de Queiroz GF, Dagli ML, Fukumasu H, Zavala AA, Matera JM. Vascular endothelial growth factor expression and microvascular density in soft tissue sarcomas in dogs. J Vet Diagn Invest 2010;22:105-8. [PMID: 20093695 DOI: 10.1177/104063871002200121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
75 Allen J, Bergsland EK. Angiogenesis in colorectal cancer: therapeutic implications and future directions. Hematology/Oncology Clinics of North America 2004;18:1087-119. [DOI: 10.1016/j.hoc.2004.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
76 Xu J, You C, Zhang S, Huang S, Cai B, Wu Z, Li H. Angiogenesis and cell proliferation in human craniopharyngioma xenografts in nude mice. J Neurosurg 2006;105:306-10. [PMID: 17328281 DOI: 10.3171/ped.2006.105.4.306] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
77 Zuckerman DS, Clark JW. Systemic therapy for metastatic colorectal cancer: current questions. Cancer 2008;112:1879-91. [PMID: 18338815 DOI: 10.1002/cncr.23409] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
78 Portera CA Jr, Berman RS, Ellis LM. Molecular determinants of colon cancer metastasis. Surg Oncol. 1998;7:183-195. [PMID: 10677169 DOI: 10.1016/s0960-7404(99)00020-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
79 Bergsland EK. When Does the Presence of the Target Predict Response to the Targeted Agent? JCO 2006;24:213-6. [DOI: 10.1200/jco.2005.03.6913] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
80 Srinivas C, Ramaiah MJ, Lavanya A, Yerramsetty S, Kavi Kishor PB, Basha SA, Kamal A, Bhadra U, Bhadra MP. Novel Etoposide Analogue Modulates Expression of Angiogenesis Associated microRNAs and Regulates Cell Proliferation by Targeting STAT3 in Breast Cancer. PLoS One. 2015;10:e0142006. [PMID: 26551008 DOI: 10.1371/journal.pone.0142006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
81 Nichols GL. Tyrosine Kinase Inhibitors as Cancer Therapy: Clinical Science Review. Cancer Investigation 2003;21:758-71. [DOI: 10.1081/cnv-120023774] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
82 Elagoz S, Egilmez R, Koyuncu A, Muslehiddinoglu A, Arici S. The intratumoral microvessel density and expression of bFGF and nm23-H1 in colorectal cancer. Pathol Oncol Res 2006;12:21-7. [PMID: 16554912 DOI: 10.1007/BF02893427] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
83 Sulkowski S, Wincewicz A, Zalewski B, Famulski W, Lotowska JM, Koda M, Sobaniec-lotowska ME, Mysliwiec M, Baltaziak M, Pawlak K, Sulkowska M. Hypoxia related growth factors and p53 in preoperative sera from patients with colorectal cancer – evaluation of the prognostic significance of these agents. Clinical Chemistry and Laboratory Medicine 2009;47. [DOI: 10.1515/cclm.2009.305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
84 Nanni O, Volpi A, Frassineti GL, De Paola F, Granato AM, Dubini A, Zoli W, Scarpi E, Turci D, Oliverio G, Gambi A, Amadori D. Role of biological markers in the clinical outcome of colon cancer. Br J Cancer 2002;87:868-75. [PMID: 12373601 DOI: 10.1038/sj.bjc.6600569] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
85 Rajaganeshan R, Prasad R, Guillou PJ, Poston G, Scott N, Jayne DG. The role of hypoxia in recurrence following resection of Dukes' B colorectal cancer. Int J Colorectal Dis 2008;23:1049-55. [PMID: 18594846 DOI: 10.1007/s00384-008-0497-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
86 Kondo Y, Arii S, Furutani M, Isigami S, Mori A, Onodera H, Chiba T, Imamura M. Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma. Cancer 2000;88:1820-7. [DOI: 10.1002/(sici)1097-0142(20000415)88:8<1820::aid-cncr10>3.0.co;2-5] [Cited by in Crossref: 46] [Article Influence: 2.2] [Reference Citation Analysis]
87 Penland SK, Goldberg RM. Combining Anti-VEGF Approaches with Oxaliplatin in Advanced Colorectal Cancer. Clinical Colorectal Cancer 2004;4:S74-80. [DOI: 10.3816/ccc.2004.s.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Goulart A, Ferreira C, Rodrigues A, Coimbra B, Sousa N, Leão P. The correlation between serum vascular endothelial growth factor (VEGF) and tumor VEGF receptor 3 in colorectal cancer. Ann Surg Treat Res 2019;97:15-20. [PMID: 31297348 DOI: 10.4174/astr.2019.97.1.15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
89 Shinto E, Ueno H, Hashiguchi Y, Hase K, Tsuda H, Matsubara O, Mochizuki H. The subserosal elastic lamina: an anatomic landmark for stratifying pT3 colorectal cancer. Dis Colon Rectum. 2004;47:467-473. [PMID: 14994112 DOI: 10.1007/s10350-003-0083-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
90 Kaya M, Wada T, Nagoya S, Sasaki M, Matsumura T, Yamashita T. The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma. J Bone Joint Surg Br 2009;91:784-8. [PMID: 19483233 DOI: 10.1302/0301-620X.91B6.21853] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
91 Fujita S, Shimoda T, Yoshimura K, Yamamoto S, Akasu T, Moriya Y. Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. J Surg Oncol. 2003;84:127-131. [PMID: 14598355 DOI: 10.1002/jso.10308] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 3.2] [Reference Citation Analysis]
92 Ishigami SI, Arii S, Furutani M, Niwano M, Harada T, Mizumoto M, Mori A, Onodera H, Imamura M. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer. 1998;78:1379-1384. [PMID: 9823983 DOI: 10.1038/bjc.1998.688] [Cited by in Crossref: 228] [Cited by in F6Publishing: 205] [Article Influence: 9.9] [Reference Citation Analysis]
93 McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Br J Cancer. 1999;79:191-203. [PMID: 9888457 DOI: 10.1038/sj.bjc.6690033] [Cited by in Crossref: 155] [Cited by in F6Publishing: 128] [Article Influence: 7.0] [Reference Citation Analysis]
94 Goh V, Padhani AR, Rasheed S. Functional imaging of colorectal cancer angiogenesis. Lancet Oncol. 2007;8:245-255. [PMID: 17329195 DOI: 10.1016/s1470-2045(07)70075-x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 19] [Article Influence: 5.1] [Reference Citation Analysis]
95 Margolin K. Inhibition of vascular endothelial growth factor in the treatment of solid tumors. Curr Oncol Rep 2002;4:20-8. [DOI: 10.1007/s11912-002-0044-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
96 Barbier A, Domont J, Magné N, Goldmard J, Genestie C, Hannoun C, Vaillant J, Bellanger A, Khayat D, Capron F, Spano J. Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab. Bulletin du Cancer 2010;97:E9-E15. [DOI: 10.1684/bdc.2010.1033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
97 Ma WW, Hidalgo M. Exploiting novel molecular targets in gastrointestinal cancers. World J Gastroenterol 2007;13:5845-56. [PMID: 17990350 DOI: 10.3748/wjg.v13.i44.5845] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
98 Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A 1998;95:8795-800. [PMID: 9671758 DOI: 10.1073/pnas.95.15.8795] [Cited by in Crossref: 295] [Cited by in F6Publishing: 256] [Article Influence: 12.8] [Reference Citation Analysis]
99 Dinami R, Porru M, Amoreo CA, Sperduti I, Mottolese M, Buglioni S, Marinelli D, Maugeri-Saccà M, Sacconi A, Blandino G, Leonetti C, Di Rocco G, Verdina A, Spinella F, Fiorentino F, Ciliberto G, Biroccio A, Zizza P. TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. J Exp Clin Cancer Res 2020;39:111. [PMID: 32539869 DOI: 10.1186/s13046-020-01612-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
100 Lim C, Broqueres-You D, Brouland JP, Merkulova-Rainon T, Faussat AM, Hilal R, Rouquie D, Eveno C, Audollent R, Levy BI. Hepatic ischemia-reperfusion increases circulating bone marrow-derived progenitor cells and tumor growth in a mouse model of colorectal liver metastases. J Surg Res. 2013;184:888-897. [PMID: 23726239 DOI: 10.1016/j.jss.2013.04.069] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
101 Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 2004;91:1354-1360. [PMID: 15376182 DOI: 10.1002/bjs.4594] [Cited by in Crossref: 160] [Cited by in F6Publishing: 157] [Article Influence: 9.4] [Reference Citation Analysis]
102 Akagi Y, Liu W, Xie K, Zebrowski B, Shaheen RM, Ellis LM. Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1beta. Br J Cancer. 1999;80:1506-1511. [PMID: 10408390 DOI: 10.1038/sj.bjc.6690553] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 2.2] [Reference Citation Analysis]
103 Karayiannakis AJ, Syrigos KN, Zbar A, Baibas N, Polychronidis A, Simopoulos C, Karatzas G. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery. 2002;131:548-555. [PMID: 12019409 DOI: 10.1067/msy.2002.123011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 2.4] [Reference Citation Analysis]
104 Collins TS, Hurwitz HI. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Seminars in Oncology 2005;32:61-8. [DOI: 10.1053/j.seminoncol.2004.09.026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
105 Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer. 2001;84:1354-1362. [PMID: 11355947 DOI: 10.1054/bjoc.2001.1809] [Cited by in Crossref: 189] [Cited by in F6Publishing: 159] [Article Influence: 9.5] [Reference Citation Analysis]
106 Cianchi F, Palomba A, Messerini L, Boddi V, Asirelli G, Perigli G, Bechi P, Taddei A, Pucciani F, Cortesini C. Tumor angiogenesis in lymph node-negative rectal cancer: Correlation with clinicopathological parameters and prognosis. Ann Surg Oncol 2002;9:20-6. [DOI: 10.1245/aso.2002.9.1.20] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
107 Yano T, Tanikawa S, Fujie T, Masutani M, Horie T. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. European Journal of Cancer 2000;36:601-9. [DOI: 10.1016/s0959-8049(99)00327-5] [Cited by in Crossref: 60] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
108 Boedefeld WM, Bland KI, Heslin MJ. Recent Insights Into Angiogenesis, Apoptosis, Invasion, and Metastasis in Colorectal Carcinoma. Ann Surg Oncol 2003;10:839-51. [DOI: 10.1245/aso.2003.02.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
109 Chapple KS, Scott N, Guillou PJ, Coletta PL, Hull MA. Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas. J Pathol 2002;198:435-41. [PMID: 12434412 DOI: 10.1002/path.1223] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
110 Tyagi P. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin Colorectal Cancer. 2005;5:24-26. [PMID: 15929803 DOI: 10.1016/s1533-0028(11)70162-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
111 Gobbi PG, Valentino F, Berardi E, Tronconi C, Brugnatelli S, Luinetti O, Moratti R, Corazza GR. New insights into the role of age and carcinoembryonic antigen in the prognosis of colorectal cancer. Br J Cancer 2008;98:328-34. [PMID: 18026187 DOI: 10.1038/sj.bjc.6604114] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
112 Kargozaran H, Kahlenberg M, Khatri VP. The Implications of Colorectal Cancer Molecular Biology in Clinical Practice. Surgical Oncology Clinics of North America 2008;17:341-55. [DOI: 10.1016/j.soc.2007.12.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
113 Tyagi P, Tripathy D. First-Line Treatment with Bevacizumab and Paclitaxel Prolongs Progression-Free Survival in Metastatic Breast Cancer. Clinical Breast Cancer 2005;6:105-7. [DOI: 10.1016/s1526-8209(11)70706-6] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
114 Chen D, Zhang Y, Shi F, Zhu H, Li M, Luo J, Chen K, Kong L, Yu J. Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients. Oncotarget. 2016;7:52436-52441. [PMID: 27203219 DOI: 10.18632/oncotarget.9420] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
115 Gomes EGDA, Jucá MJ, Menezes HLD, Nunes BLBBP, Costa H, Lima FDO, Matos D. Correlation between the immunohistochemical expressions of MMP-1, MMP-7 and VEGF and prognostic factors in colorectal adenocarcinoma. Acta Cir Bras 2009;24:303-10. [DOI: 10.1590/s0102-86502009000400010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
116 Gu S, Liu CJ, Qiao T, Sun XM, Chen LL, Zhang L. Inhibitory effect of antisense vascular endothelial growth factor 165 eukaryotic expression vector on proliferation of hepatocellular carcinoma cells. World J Gastroenterol 2004;10:535-9. [PMID: 14966912 DOI: 10.3748/wjg.v10.i4.535] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
117 Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I. Prognostic Significance of Microvessel Density and Vascular Endothelial Growth Factor (VEGF) Expression in non-Hodgkin's Lymphoma. Leukemia & Lymphoma 2011;44:2089-93. [DOI: 10.1080/1042819031000123519] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
118 Bhaskara A, Eng C. Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. Clin Colorectal Cancer. 2008;7:65-68. [PMID: 18279580 DOI: 10.3816/ccc.2008.n.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
119 Cascinu S, Del Ferro E, Ligi M, Staccioli MP, Giordani P, Catalano V, Agostinelli R, Muretto P, Catalano G. Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest. 2001;19:8-12. [PMID: 11291560 DOI: 10.1081/CNV-100000069] [Cited by in Crossref: 33] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
120 Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 2009;69:3842-9. [PMID: 19383922 DOI: 10.1158/0008-5472.CAN-08-2246] [Cited by in Crossref: 109] [Cited by in F6Publishing: 58] [Article Influence: 9.1] [Reference Citation Analysis]
121 Logan-Collins JM, Lowy AM, Robinson-Smith TM, Kumar S, Sussman JJ, James LE, Ahmad SA. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol. 2008;15:738-744. [PMID: 18043973 DOI: 10.1245/s10434-007-9699-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
122 Ma Z, Yang Y, Yang G, Wan J, Li G, Lu P, Du L. Iodine-125 induces apoptosis via regulating p53, microvessel density, and vascular endothelial growth factor in colorectal cancer. World J Surg Oncol 2014;12:222. [PMID: 25033896 DOI: 10.1186/1477-7819-12-222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
123 Kil WJ, Tofilon PJ, Camphausen K. Post-radiation increase in VEGF enhances glioma cell motility in vitro. Radiat Oncol 2012;7:25. [PMID: 22356893 DOI: 10.1186/1748-717X-7-25] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 5.8] [Reference Citation Analysis]
124 Ferroni P, Spila A, Martini F, D'Alessandro R, Mariotti S, Del Monte G, Graziano P, Buonomo O, Guadagni F, Roselli M. Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancer. Oncology. 2005;69:145-153. [PMID: 16146041 DOI: 10.1159/000087838] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
125 Krebs B, Kozelj M, Kavalar R, Gajzer B, Gadzijev EM. Prognostic value of additional pathological variables for long-term survival after curative resection of rectal cancer. World J Gastroenterol 2006;12:4565-8. [PMID: 16874874 DOI: 10.3748/wjg.v12.i28.4565] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
126 Ahmad SA, Liu W, Jung YD, Fan F, Reinmuth N, Bucana CD, Ellis LM. Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma: A possible mechanism for the initiation of angiogenesis. Cancer 2001;92:1138-43. [DOI: 10.1002/1097-0142(20010901)92:5<1138::aid-cncr1431>3.0.co;2-l] [Cited by in Crossref: 68] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
127 Ahmad SA, Berman RS, Ellis LM. Biology of colorectal liver metastases. Surg Oncol Clin N Am. 2003;12:135-150. [PMID: 12735135 DOI: 10.1016/S1055-3207(02)00078-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
128 Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer 2012;11:1-13. [PMID: 21752724 DOI: 10.1016/j.clcc.2011.05.005] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 8.2] [Reference Citation Analysis]
129 Haier J, Nasralla M, Nicolson GL. Cell surface molecules and their prognostic values in assessing colorectal carcinomas. Ann Surg 2000;231:11-24. [PMID: 10636097 DOI: 10.1097/00000658-200001000-00003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
130 Franceschi F, Genta RM, Gasbarrini A, Gentiloni Silveri N, Gasbarrini G, Sepulveda AR. Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma. Dig Liver Dis. 2002;34:621-625. [PMID: 12405247 DOI: 10.1016/s1590-8658(02)80203-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
131 Ellis LM, Staley CA, Liu W, Fleming RYD, Parikh NU, Bucana CD, Gallick GE. Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific for c-src. Journal of Biological Chemistry 1998;273:1052-7. [DOI: 10.1074/jbc.273.2.1052] [Cited by in Crossref: 133] [Cited by in F6Publishing: 107] [Article Influence: 5.8] [Reference Citation Analysis]
132 Klem J, Chu E, Jain VK. Current Studies with PTK787, an Oral Inhibitor of Vascular Endothelial Growth Factor in Colorectal Cancer. Clinical Colorectal Cancer 2003;3:147-9. [DOI: 10.1016/s1533-0028(11)70081-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
133 Tol J, Punt CJA. Targeted therapy in advanced colorectal cancer, an update. Targ Oncol 2007;2:165-72. [DOI: 10.1007/s11523-007-0052-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
134 Drevs J, Zirrgiebel U, Schmidt-gersbach C, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas A, Unger C, Henry A, Steward W, Laurent D, Lebwohl D, Dugan M, Marmé D. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Annals of Oncology 2005;16:558-65. [DOI: 10.1093/annonc/mdi118] [Cited by in Crossref: 101] [Cited by in F6Publishing: 81] [Article Influence: 6.3] [Reference Citation Analysis]
135 Takeda A, Stoeltzing O, Ahmad SA, Reinmuth N, Liu W, Parikh A, Fan F, Akagi M, Ellis LM. Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol 2002;9:610-6. [PMID: 12167573 DOI: 10.1007/BF02574475] [Cited by in Crossref: 57] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
136 Demirkesen C, Büyükpinarbaşili N, Ramazanoğlu R, Oğuz O, Mandel NM, Kaner G. The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblastic growth factor. Pathology 2006;38:132-7. [PMID: 16581653 DOI: 10.1080/00313020600557565] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
137 Tsai WS, Changchien CR, Yeh CY, Chen JS, Tang R, Chiang JM, Hsieh PS, Fan CW, Wang JY. Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer. Dis Colon Rectum. 2006;49:883-894. [PMID: 16741643 DOI: 10.1007/s10350-006-0528-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
138 Kafousi M, Vrekoussis T, Tsentelierou E, Pavlakis K, Navrozoglou I, Dousias V, Sanidas E, Tsiftsis D, Georgoulias V, Stathopoulos EN. Immunohistochemical study of the angiogenetic network of VEGF, HIF1α, VEGFR-2 and endothelial nitric oxide synthase (eNOS) in human breast cancer. Pathol Oncol Res 2012;18:33-41. [PMID: 21671140 DOI: 10.1007/s12253-011-9413-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
139 Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-65. [PMID: 12506171 DOI: 10.1200/jco.2003.10.066] [Cited by in Crossref: 1199] [Cited by in F6Publishing: 313] [Article Influence: 66.6] [Reference Citation Analysis]
140 Sorscher SM. Biological therapy update in colorectal cancer. Expert Opin Biol Ther 2007;7:509-19. [PMID: 17373902 DOI: 10.1517/14712598.7.4.509] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
141 Bruns H, Kazanavicius D, Schultze D, Saeedi MA, Yamanaka K, Strupas K, Schemmer P. Glycine inhibits angiogenesis in colorectal cancer: role of endothelial cells. Amino Acids 2016;48:2549-58. [PMID: 27351202 DOI: 10.1007/s00726-016-2278-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
142 Ueno H, Hase K, Mochizuki H. Criteria for extramural perineural invasion as a prognostic factor in rectal cancer. British Journal of Surgery 2001;88:994-1000. [DOI: 10.1046/j.0007-1323.2001.01810.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
143 Ellis L. Is determination of angiogenic activity in human tumours clinically useful? European Journal of Cancer 1998;34:609-13. [DOI: 10.1016/s0959-8049(97)10040-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
144 Meyers MO, Watson JC. Angiogenesis and hepatic colorectal metastases. Surg Oncol Clin N Am 2003;12:151-63. [PMID: 12735136 DOI: 10.1016/s1055-3207(02)00083-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
145 Perrone G, Vincenzi B, Santini D, Verzì A, Tonini G, Vetrani A, Rabitti C. Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer. Cancer Lett. 2004;208:227-234. [PMID: 15142682 DOI: 10.1016/j.canlet.2003.11.032] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
146 Takahashi Y, Bucana CD, Cleary KR, Ellis LM. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer 1998;79:34-8. [PMID: 9495355 DOI: 10.1002/(sici)1097-0215(19980220)79:1<34::aid-ijc7>3.0.co;2-x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
147 Santini D, Vincenzi B, Perrone G, Rabitti C, Borzomati D, Valeri S, Coppola R, Magistrelli P, Tonini G. Vascular endothelial growth factor (VEGF) expression is not associated with prognosis in patients with radically resected ampullary carcinoma. Ann Oncol 2005;16:1847-8. [PMID: 15972277 DOI: 10.1093/annonc/mdi353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
148 Berman RS, Portera CA Jr, Ellis LM. Biology of liver metastases. Cancer Treat Res 2001;109:183-206. [PMID: 11775436 DOI: 10.1007/978-1-4757-3371-6_10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
149 Lurje G, Hendifar AE, Schultheis AM, Pohl A, Husain H, Yang D, Manegold PC, Ning Y, Zhang W, Lenz HJ. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. Pharmacogenet Genomics 2009;19:95-102. [PMID: 18987561 DOI: 10.1097/FPC.0b013e32831a9ad1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
150 Guba M, Seeliger H, Kleespies A, Jauch K, Bruns C. Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis 2004;19:510-7. [DOI: 10.1007/s00384-003-0576-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
151 Poon RT, Fan ST, Wong J. Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches. Ann Surg. 2003;238:9-28. [PMID: 12832961 DOI: 10.1097/01.sla.0000075047.47175.35] [Cited by in Crossref: 28] [Cited by in F6Publishing: 36] [Article Influence: 1.6] [Reference Citation Analysis]
152 Galindo-Gallego M, Fernández-Aceñero MJ, Sanz-Ortega J, Aljama A, López-Elzaurdia C. Prognostic significance of microvascular counts in rectal carcinoma. Pathol Res Pract 2000;196:607-12. [PMID: 10997734 DOI: 10.1016/S0344-0338(00)80002-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
153 Lim JJ, Kang S, Lee MR, Pai HK, Yoon HJ, Lee JI, Hong SP, Lim CY. Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis. J Oral Pathol Med. 2003;32:552-561. [PMID: 12969230 DOI: 10.1034/j.1600-0714.2003.00073.x-i1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
154 Vermeulen PB, Van den Eynden GG, Huget P, Goovaerts G, Weyler J, Lardon F, Van Marck E, Hubens G, Dirix LY. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer 1999;79:316-22. [PMID: 9888475 DOI: 10.1038/sj.bjc.6690051] [Cited by in Crossref: 104] [Cited by in F6Publishing: 87] [Article Influence: 4.7] [Reference Citation Analysis]
155 Lesslie DP, Summy JM, Parikh NU, Fan F, Trevino JG, Sawyer TK, Metcalf CA, Shakespeare WC, Hicklin DJ, Ellis LM, Gallick GE. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer 2006;94:1710-7. [PMID: 16685275 DOI: 10.1038/sj.bjc.6603143] [Cited by in Crossref: 96] [Cited by in F6Publishing: 77] [Article Influence: 6.4] [Reference Citation Analysis]
156 Taguchi E, Nakamura K, Miura T, Shibuya M, Isoe T. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Sci 2008;99:623-30. [PMID: 18201272 DOI: 10.1111/j.1349-7006.2007.00724.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
157 Tarta C, Teixeira CR, Tanaka S, Haruma K, Chiele-Neto C, da Silva VD. Angiogenesis in advanced colorectal adenocarcinoma with special reference to tumoral invasion. Arq Gastroenterol 2002;39:32-8. [PMID: 12184164 DOI: 10.1590/s0004-28032002000100007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
158 Chin KF, Greenman J, Gardiner E, Kumar H, Topping K, Monson J. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer. 2000;83:1425-1431. [PMID: 11076648 DOI: 10.1054/bjoc.2000.1508] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 2.9] [Reference Citation Analysis]
159 Yang X, Wang Y, Liu F, Zeng K, Qian M, Chen G, Shi L, Zhu G. Increased invasiveness of osteosarcoma mesenchymal stem cells induced by bone-morphogenetic protein-2. In Vitro Cell Dev Biol -Animal 2013;49:270-8. [DOI: 10.1007/s11626-013-9598-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
160 Díaz-Rubio E, Schmoll HJ. The future development of bevacizumab in colorectal cancer. Oncology 2005;69 Suppl 3:34-45. [PMID: 16301834 DOI: 10.1159/000088482] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
161 Yang C, Chu K, Yeh W. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urologic Oncology: Seminars and Original Investigations 2004;22:1-6. [DOI: 10.1016/s1078-1439(03)00015-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
162 Skarda J, Kolar Z, Janikova M, Radova L, Kolek V, Fridman E, Kopolovic J. Analysis of the prognostic impact of nestin expression in non-small cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012;156:135-42. [DOI: 10.5507/bp.2012.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
163 Poon RT, Fan ST, Wong J. Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches. Ann Surg. 2003;238:9-28. [PMID: 12832961 DOI: 10.1097/00000658-200307000-00003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
164 Abe A, Fukui H, Fujii S, Fujita M, Mukawa K, Ichikawa K, Tomita S, Ono Y, Imai Y, Imura J. Involvement of cyclooxygenase-2 and vascular endothelial growth factor in vascularization and lymph node metastasis of colorectal cancers with submucosal invasion. J Gastroenterol Hepatol. 2007;22:1071-1077. [PMID: 17608853 DOI: 10.1111/j.1440-1746.2006.04778.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
165 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 2007;13:6231-5. [PMID: 18069765 DOI: 10.3748/wjg.v13.i46.6231] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
166 Pasche B, Mulcahy M, Benson AB. Molecular markers in prognosis of colorectal cancer and prediction of response to treatment. Best Practice & Research Clinical Gastroenterology 2002;16:331-45. [DOI: 10.1053/bega.2002.0289] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
167 Toiyama Y, Miki C, Inoue Y, Okugawa Y, Koike Y, Yokoe T, Tanaka K, Kusunoki M. Soluble intercellular adhesion molecule-1 as a prognostic marker for stage II colorectal cancer patients. Ann Surg Oncol. 2008;15:1617-1624. [PMID: 18368454 DOI: 10.1245/s10434-008-9874-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
168 Chen D, Song X, Shi F, Zhu H, Wang H, Zhang N, Zhang Y, Kong L, Yu J. Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion. Oncotarget 2017;8:35262-71. [PMID: 27823984 DOI: 10.18632/oncotarget.13064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
169 Bupathi M, Ahn DH, Bekaii-Saab T. Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointest Cancer 2016;6:21-30. [PMID: 28190957 DOI: 10.2147/GICTT.S97740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
170 Nicolini A, Campani D, Miccoli P, Spinelli C, Carpi A, Menicagli M, Ferrari P, Gadducci G, Rossi G, Fini M, Giavaresi G, Bonazzi V, Giardino R. Vascular Endothelial Growth Factor (Vegf) and Other Common Tissue Prognostic Indicators in Breast Cancer: A Case-Control Study. Int J Biol Markers 2004;19:275-81. [DOI: 10.1177/172460080401900404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
171 Whisenant J, Bergsland E. Anti-angiogenic strategies in gastrointestinal malignancies. Curr Treat Options Oncol. 2005;6:411-421. [PMID: 16107244 DOI: 10.1007/s11864-005-0044-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
172 Rodriguez-bigas MA, Stoler DL, Bertario L, Anderson GR, Baba S. Colorectal Cancer. Surgical Oncology Clinics of North America 2000;9:643-52. [DOI: 10.1016/s1055-3207(18)30098-x] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
173 Kim JW, Kim TD, Hong BS, Kim OY, Yoon WH, Chae CB, Gho YS. A serum-stable branched dimeric anti-VEGF peptide blocks tumor growth via anti-angiogenic activity. Exp Mol Med 2010;42:514-23. [PMID: 20543548 DOI: 10.3858/emm.2010.42.7.052] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
174 Wray CJ, Rilo HL, Ahmad SA. Colon cancer angiogenesis and antiangiogenic therapy. Expert Opinion on Investigational Drugs 2005;13:631-41. [DOI: 10.1517/13543784.13.6.631] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
175 Yang CC, Chu KC, Yeh WM. Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement. J Clin Lab Anal 2003;17:85-9. [PMID: 12696078 DOI: 10.1002/jcla.10074] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
176 Reinmuth N, Parikh AA, Ahmad SA, Liu W, Stoeltzing O, Fan F, Takeda A, Akagi M, Ellis LM. Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech. 2003;60:199-207. [PMID: 12539174 DOI: 10.1002/jemt.10258] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 4.2] [Reference Citation Analysis]
177 Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, Husain H, Gordon MA, Nagashima F, Chang HM, Lenz HJ. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol 2008;19:1734-41. [PMID: 18550579 DOI: 10.1093/annonc/mdn368] [Cited by in Crossref: 91] [Cited by in F6Publishing: 77] [Article Influence: 7.0] [Reference Citation Analysis]
178 Okuno K, Yasutomi M, Nishimura N, Arakawa T, Shiomi M, Hida J, Ueda K, Minami K. Gene expression analysis in colorectal cancer using practical DNA array filter. Dis Colon Rectum. 2001;44:295-299. [PMID: 11227951 DOI: 10.1007/BF02234309] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
179 Jung YD, Kim MS, Shin BA, Chay KO, Ahn BW, Liu W, Bucana CD, Gallick GE, Ellis LM. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer. 2001;84:844-850. [PMID: 11259102 DOI: 10.1054/bjoc.2000.1691] [Cited by in Crossref: 228] [Cited by in F6Publishing: 192] [Article Influence: 11.4] [Reference Citation Analysis]
180 Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 1999;6:373-378. [PMID: 10379858 DOI: 10.1007/s10434-999-0373-0] [Cited by in Crossref: 176] [Cited by in F6Publishing: 144] [Article Influence: 8.0] [Reference Citation Analysis]
181 Tokunaga T, Nakamura M, Oshika Y, Abe Y, Ozeki Y, Fukushima Y, Hatanaka H, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Tamaoki N, Ueyama Y. Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer 1999;79:354-9. [PMID: 9888480 DOI: 10.1038/sj.bjc.6690056] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 3.4] [Reference Citation Analysis]
182 van Halteren HK, Peters HM, van Krieken JHJM, Coebergh JW, Roumen RMH, van der Worp E, Wagener JT, Vreugdenhil G. Tumor growth pattern and thymidine phosphorylase expression are related with the risk of hematogenous metastasis in patients with Astler Coller B1/B2 colorectal carcinoma. Cancer 2001;91:1752-7. [DOI: 10.1002/1097-0142(20010501)91:9<1752::aid-cncr1194>3.0.co;2-m] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
183 Tien YW, Chang KJ, Chiu YF, Huang KW, Lee PH. Comparison of angiogenic factor levels in tumor drainage and peripheral venous blood from colorectal cancer patients. Ann Surg Oncol. 2006;13:1357-1363. [PMID: 17001510 DOI: 10.1245/s10434-006-9042-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
184 Boku N, Ohtsu A, Yoshida S, Shirao K, Shimada Y, Hyodo I, Saito H, Miyata Y. Significance of Biological Markers for Predicting Prognosis and Selecting Chemotherapy Regimens of Advanced Gastric Cancer Patients between Continuous Infusion of 5-FU and a Combination of 5-FU and Cisplatin. Japanese Journal of Clinical Oncology 2007;37:275-81. [DOI: 10.1093/jjco/hym015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
185 Hong HS, Kim SH, Park HJ, Park MS, Kim KW, Kim WH, Kim NK, Lee JM, Cho HJ. Correlations of dynamic contrast-enhanced magnetic resonance imaging with morphologic, angiogenic, and molecular prognostic factors in rectal cancer. Yonsei Med J. 2013;54:123-130. [PMID: 23225808 DOI: 10.3349/ymj.2013.54.1.123] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
186 Galindo Gallego M, Fernández Aceñero MJ, Sanz Ortega J, Aljama A. Vascular enumeration as a prognosticator for colorectal carcinoma. Eur J Cancer 2000;36:55-60. [PMID: 10741295 DOI: 10.1016/s0959-8049(99)00243-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
187 Giordano G, Febbraro A, Venditti M, Campidoglio S, Olivieri N, Raieta K, Parcesepe P, Imbriani GC, Remo A, Pancione M. Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. Gastroenterol Res Pract. 2014;2014:526178. [PMID: 25136356 DOI: 10.1155/2014/526178] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
188 Gonzalez FJ, Quesada AR, Sevilla I, Baca JJ, Medina MA, Amores J, Diaz JM, Rius-Diaz F, Marques E, Alba E. Prognostic value of serum angiogenic activity in colorectal cancer patients. J Cell Mol Med 2007;11:120-8. [PMID: 17367506 DOI: 10.1111/j.1582-4934.2007.00005.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
189 Cristi E, Perrone G, Toscano G, Verzì A, Nori S, Santini D, Tonini G, Vetrani A, Fabiano A, Rabitti C. Tumour proliferation, angiogenesis, and ploidy status in human colon cancer. J Clin Pathol 2005;58:1170-4. [PMID: 16254106 DOI: 10.1136/jcp.2004.025536] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
190 Troiani T, Martinelli E, Orditura M, De Vita F, Ciardiello F, Morgillo F. Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. Expert Opinion on Investigational Drugs 2012;21:949-59. [DOI: 10.1517/13543784.2012.689287] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
191 Rasheed S, McDonald PJ, Northover JM, Guenther T. Angiogenesis and hypoxic factors in colorectal cancer. Pathol Res Pract 2008;204:501-10. [PMID: 18541387 DOI: 10.1016/j.prp.2008.03.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
192 Ellis LM. Angiogenesis and its role in colorectal tumor and metastasis formation. Semin Oncol 2004;31:3-9. [PMID: 15696024 DOI: 10.1053/j.seminoncol.2004.11.028] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
193 Tsuji T, Sasaki Y, Tanaka M, Hanabata N, Hada R, Munakata A. Microvessel Morphology and Vascular Endothelial Growth Factor Expression in Human Colonic Carcinoma With or Without Metastasis. Lab Invest 2002;82:555-62. [DOI: 10.1038/labinvest.3780450] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
194 Gradishar WJ. Endpoints for Determination of Efficacy of Antiangiogenic Agents in Clinical Trials. In: Teicher BA, editor. Antiangiogenic Agents in Cancer Therapy. Totowa: Humana Press; 1999. pp. 341-53. [DOI: 10.1007/978-1-59259-453-5_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
195 Yamamura T, Tsukikawa S, Yamada K, Yamaguchi S. Morphologic analysis of microvessels in colorectal tumors with respect to the formation of liver metastases. J Surg Oncol 2001;78:259-64. [DOI: 10.1002/jso.1164] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
196 Moghimi-Dehkordi B, Safaee A. An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol. 2012;4:71-75. [PMID: 22532879 DOI: 10.4251/wjgo.v4.i4.71] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 76] [Article Influence: 8.6] [Reference Citation Analysis]
197 Citak EC, Oguz A, Karadeniz C, Akyurek N. ROLE OF GELATINASES (MMP-2 AND MMP-9), TIMP-1, VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), AND MICROVESSEL DENSITY ON THE CLINICOPATHOLOGICAL BEHAVIOR OF CHILDHOOD NON-HODGKIN LYMPHOMA. Pediatric Hematology and Oncology 2009;25:55-66. [DOI: 10.1080/08880010701826866] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
198 Garcea G, Lloyd T, Gescher A, Dennison A, Steward W, Berry D. Angiogenesis of gastrointestinal tumours and their metastases – a target for intervention? European Journal of Cancer 2004;40:1302-13. [DOI: 10.1016/j.ejca.2004.02.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
199 Kataoka H, Igarashi H, Kanamori M, Ihara M, Wang JD, Wang YJ, Li ZY, Shimamura T, Kobayashi T, Maruyama K, Nakamura T, Arai H, Kajimura M, Hanai H, Tanaka M, Sugimura H. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci 2004;95:136-41. [PMID: 14965363 DOI: 10.1111/j.1349-7006.2004.tb03194.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 3.9] [Reference Citation Analysis]
200 Staton CA, Chetwood AS, Cameron IC, Cross SS, Brown NJ, Reed MW. The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal cancer. Gut. 2007;56:1426-1432. [PMID: 17566019 DOI: 10.1136/gut.2007.125286] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
201 Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol. 2006;33:S1-S7. [PMID: 17145519 DOI: 10.1053/j.seminoncol.2006.08.002] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 6.6] [Reference Citation Analysis]
202 Salmon JS, Lockhart AC, Berlin J. Anti-angiogenic treatment of gastrointestinal malignancies. Cancer Invest. 2005;23:712-726. [PMID: 16377590 DOI: 10.1080/07357900500360024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
203 Hoff PM. Future directions in the use of antiangiogenic agents in patients with colorectal cancer. Seminars in Oncology 2004;31:17-21. [DOI: 10.1053/j.seminoncol.2004.11.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
204 Rastogi S, Kumar R, Sankineani SR, Marimuthu K, Rijal L, Prakash S, Jalan D, Khan SA, Sharma MC. Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study. Int Orthop 2012;36:2315-21. [PMID: 23015149 DOI: 10.1007/s00264-012-1663-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
205 Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001;19:1207-1225. [PMID: 11181687 DOI: 10.1200/jco.2001.19.4.1207] [Cited by in Crossref: 414] [Cited by in F6Publishing: 114] [Article Influence: 20.7] [Reference Citation Analysis]
206 Ishiwata T, Matsuda Y, Naito Z. Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis. World J Gastroenterol. 2011;17:409-418. [PMID: 21274370 DOI: 10.3748/wjg.v17.i4.409] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 74] [Article Influence: 8.8] [Reference Citation Analysis]
207 Kwon KA, Kim SH, Oh SY, Lee S, Han JY, Kim KH, Goh RY, Choi HJ, Park KJ, Roh MS. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer. 2010;10:203. [PMID: 20465852 DOI: 10.1186/1471-2407-10-203] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 6.3] [Reference Citation Analysis]
208 Uribarrena A R, Ortego J, Fuentes J, Raventós N, Parra P, Uribarrena E R. Prognostic value of microvascular density in dukes a and B (t1-t4, n0, m0) colorectal carcinomas. Gastroenterol Res Pract 2009;2009:679830. [PMID: 19902004 DOI: 10.1155/2009/679830] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
209 Schmieder R, Hoffmann J, Becker M, Bhargava A, Müller T, Kahmann N, Ellinghaus P, Adams R, Rosenthal A, Thierauch KH, Scholz A, Wilhelm SM, Zopf D. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer 2014;135:1487-96. [PMID: 24347491 DOI: 10.1002/ijc.28669] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 9.9] [Reference Citation Analysis]
210 Sagaert X. Prognostic biomarkers in colorectal cancer: where do we stand? Virchows Arch. 2014;464:379-391. [PMID: 24487787 DOI: 10.1007/s00428-013-1532-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
211 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 2007;13:6231-6235. [PMID: 18069765 DOI: 10.3748/wjg.13.6231] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
212 Mancuso A, Sternberg CN. Colorectal cancer and antiangiogenic therapy: What can be expected in clinical practice? Critical Reviews in Oncology/Hematology 2005;55:67-81. [DOI: 10.1016/j.critrevonc.2005.03.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]